Search

Displaying results 3411 - 3420 of 5897 in total
  1. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

  2. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine.

  3. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.

  4. Drug

    Amiloride

    go.drugbank.com/drugs/DB00594
    ApprovedInvestigational

    Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

  5. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen Mix
  6. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy. … CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

  7. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).

  8. Drug

    Sagopilone

    go.drugbank.com/drugs/DB12391
    Investigational

    It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer. … Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different

  9. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo.

  10. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin